Advertisement
Advertisement
GSK
GSK plc - ADR
60.22
USDSponsored
+1.05
+1.77%
Feb 06, 15:59 UTC -5
Closed
After-Market
59.98
-0.23
-0.38%
GSK Earnings Reports
Positive Surprise Ratio
GSK beat 33 of 40 last estimates.
83%
Next Report
Date of Next Report
Apr 28, 2026
Estimate for Q1 26 (Revenue/ EPS)
$7.95B
/$0.45
Implied change from Q4 25 (Revenue/ EPS)
-4.88%
/-8.16%
Implied change from Q1 25 (Revenue/ EPS)
+5.80%
/+2.27%
GSK plc - ADR earnings per share and revenue
On Feb 04, 2026, GSK reported earnings of 0.49 USD per share (EPS) for Q4 25, beating the estimate of 0.23 USD, resulting in a 111.36% surprise. Revenue reached 8.36 billion, compared to an expected 8.73 billion, with a -4.20% difference. The market reacted with a +7.29% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 5 analysts forecast an EPS of 0.45 USD, with revenue projected to reach 7.95 billion USD, implying an decrease of -8.16% EPS, and decrease of -4.88% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
FAQ
What were GSK plc - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, GSK plc - ADR reported EPS of $0.49, beating estimates by 111.36%, and revenue of $8.36B, -4.2% below expectations.
How did the market react to GSK plc - ADR's Q4 2025 earnings?
The stock price moved up 7.29%, changed from $53.34 before the earnings release to $57.23 the day after.
When is GSK plc - ADR expected to report next?
The next earning report is scheduled for Apr 28, 2026.
What are the forecasts for GSK plc - ADR's next earnings report?
Based on 5
analysts, GSK plc - ADR is expected to report EPS of $0.45 and revenue of $7.95B for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement